ArticleEClinicalMedicine2024

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.

Ashwath Gurumurthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.